Results 1 to 10 of about 30,894 (205)
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]
, 2014 Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Lyubov Zaitseva +6 more
core +7 more sources
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma [PDF]
Cancer Discovery, 2017 Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-κB. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown.
Christian Grommes +2 more
exaly +3 more sources
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study [PDF]
Leukemia, 2019 RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Jan A Burger, Paul M Barr, Tadeusz Robak
exaly +5 more sources
Efficacy in the margins of NHL with ibrutinib [PDF]
Blood, 2017 In this issue of Blood, Noy et al report on the efficacy of single-agent ibrutinib in patients with relapsed or refractory marginal zone lymphoma (MZL). They demonstrate an overall response rate of 48% and a median progression-free survival of 14 months, establishing the Bruton tyrosine kinase (BTK) inhibitor ibrutinib as a therapeutic option for this ...
Paul M. Barr
openalex +4 more sources
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [PDF]
New England Journal of Medicine, 2013 John C Byrd, Ian W Flinn, Jan A Burger
exaly +2 more sources
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK [PDF]
Proceedings of the National Academy of Sciences of the United States of America, 2015 Idit Sagiv-Barfi, Ronald Levy
exaly +2 more sources
Proceedings of the National Academy of Sciences of the United States of America, 2014 Rajarshi Guha, Ryan M Young, Adam Yasgar
exaly +2 more sources
Extrahepatic metabolism of ibrutinib [PDF]
Investigational New Drugs, 2020 SummaryIbrutinib is a first-in-class Bruton’s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally their excretion in feces and urine occurs. These metabolites, however, can reach substantial concentrations
Rosalinde Masereeuw +13 more
openaire +5 more sources
Arrhythmia Patterns in Patients on Ibrutinib [PDF]
Frontiers in Cardiovascular Medicine, 2022 Introduction: Ibrutinib, a Bruton's tyrosine kinase inhibitor (TKI) used primarily in the treatment of hematologic malignancies, has been associated with increased incidence of atrial fibrillation (AF), with limited data on its association with other tachyarrhythmias.
Muhammad Fazal +9 more
openaire +3 more sources